Sucralfate is NOT Recommended for Functional Dyspepsia
Sucralfate should not be used to treat functional dyspepsia, as it is not supported by current evidence-based guidelines and has failed to demonstrate efficacy superior to placebo in high-quality trials. The most recent and authoritative British Society of Gastroenterology (BSG) guidelines from 2022 1 do not include sucralfate among recommended treatments for functional dyspepsia, despite conducting comprehensive meta-analyses of available therapies.
Why Sucralfate Fails in Functional Dyspepsia
The evidence against sucralfate is compelling:
Systematic review evidence: A 2003 meta-analysis found that sucralfate was not statistically significantly superior to placebo for non-ulcer dyspepsia 2. This contrasts sharply with prokinetics (48% relative risk reduction) and H2-receptor antagonists (22% relative risk reduction), both of which showed clear benefit.
Randomized controlled trial data: The highest quality double-blind RCT from 1993 involving 104 patients found no difference between sucralfate and placebo (68% vs 69% improvement respectively) 3. This directly contradicts the positive findings of an older 1987 trial 4, and the more recent, higher-quality negative study should take precedence.
Guideline omission: The 2022 BSG guidelines 1 explicitly reviewed drug efficacy through comprehensive literature searches and network meta-analyses, yet sucralfate is conspicuously absent from all treatment recommendations. Similarly, the 2025 Italian guidelines 5 recommend against the routine use of mucosal protectants in FD management.
What Actually Works: Evidence-Based Alternatives
The BSG guidelines 1 provide clear treatment pathways:
First-line approach:
- PPIs at standard dose for a short course, regardless of symptom subtype
- H. pylori eradication if testing is positive (all patients should be tested)
Second-line options:
- Prokinetics (preferentially for postprandial distress syndrome subtype)
- Tricyclic antidepressants (particularly effective for epigastric pain syndrome)
- Mirtazapine (especially beneficial for patients with weight loss) 5
Refractory cases:
- Cognitive behavioral therapy
- Multidisciplinary team involvement
Critical Pitfalls to Avoid
Don't prescribe based on mechanism alone: While sucralfate has theoretical mucosal protective properties 6, functional dyspepsia is a disorder of gut-brain interaction 1, not primarily a mucosal injury condition. The pathophysiology involves altered motility, visceral hypersensitivity, and central nervous system processing—mechanisms that sucralfate does not address.
Beware of outdated practices: Despite a 2025 analysis showing sucralfate continues to be prescribed with significant economic burden 7, this represents clinical inertia rather than evidence-based practice. The authors explicitly question its ongoing prescription given the limited evidence base.
Don't confuse indications: Sucralfate is FDA-approved for duodenal ulcer treatment 8, not functional dyspepsia. The drug label makes no mention of functional dyspepsia as an indication.
The Bottom Line
Choose PPIs, H. pylori eradication, or neuromodulators (TCAs, mirtazapine) as evidence-based first and second-line therapies for functional dyspepsia. Sucralfate lacks both guideline support and convincing trial evidence, making it an inappropriate choice that delays effective treatment and wastes healthcare resources 7.